Bli medlem
Bli medlem

Du är här


BioGaia: BioGaia associated MetaboGen starts study on Intrahepatic Cholestasis of Pregnancy with Ferring

MetaboGen AB and Ferring Pharmaceuticals announce a research
collaboration aimed at developing a microbiome-based product to
prevent and treat Intrahepatic Cholestasis of Pregnancy (ICP). In
December recruitment of patients for the first clinical trial begins.

BioGaia holds 36 percent of the research company MetaboGen.

MetaboGen has developed and patented a concept for how the microbiome
(the overall expression of microbial genes) could affect intrahepatic
cholestasis of pregnancy, a disorder affecting around 400,000
pregnant women annually.

Recruitment of patients for the first clinical study begun 6 December
2016. The 18-month long study is conducted in cooperation with the
Women's Clinic in Lund, Sweden. 100 pregnant women will be included
in the trial.

BioGaia's interest in MetaboGen unchanged

In December 2014 BioGaia took the decision to invest SEK 12 million in
MetaboGen AB, and BioGaia's Group President Peter Rothschild became
Chairman of the Board of the company. The investment was to be made
over a two-year period and the last of three investments was done 30
November 2016. BioGaia's share of MetaboGen today amounts to 36
percent and BioGaia has no current plans of changing this.

"BioGaia's investment in MetaboGen is long term and aims at developing
the next generation of probiotic products, based on in-depth analyses
of the microbiome. The research field is expanding rapidly and
several large pharmaceutical companies have invested in microbiome
companies. We are very positive about MetaboGen's collaboration with
Ferring, which is an ideal partner for this type of product. It is
also satisfying that MetaboGen already is underway with a clinical
trial", says Peter Rothschild, Group President BioGaia.

What is Intrahepatic Cholestasis of Pregnancy (ICP)?
Intrahepatic cholestasis of pregnancy (ICP) is a disorder that can
develop in pregnancy. ICP affects about 400,000 pregnant women
annually and is a recurrent disease: 70 per cent of women who have
been diagnosed with ICP during their first pregnancy will be affected
again in following pregnancies. In addition to itching, which may be
intense and very uncomfortable for the mother, there are links
between ICP and preterm birth and gestational diabetes.

About Ferring Pharmaceuticals
Headquartered in Switzerland, Ferring Pharmaceuticals is a
research-driven, specialty biopharmaceutical group active in global
markets. The company identifies, develops and markets innovative
products in the areas of reproductive health, urology,
gastroenterology, endocrinology and orthopaedics. Ferring has its own
operating subsidiaries in nearly 60 countries and markets its
products in more than 100 countries.

About MetaboGen AB
MetaboGen is a research-driven company with a focus on the microbiome
and its impact on health. The company was founded in Gothenburg,
Sweden and is based on break-through science from the labs of
Professor Fredrik Bäckhed (University of Gothenburg) and Professor
Jens B Nielsen (Chalmers University of Technology). Since 2011,
MetaboGen develops products based on advanced mapping of the
intestinal microflora composition. In 2014 BioGaia AB invested in the
company. MetaboGen's technology, along with more than 25 years of
experience in the development of probiotics from BioGaia, provides
the company with a unique opportunity to develop the next generation
of microbial products.

For additional information, please contact
Peter Rothschild, Group President, BioGaia: 46 8 555 293 00

Axel Sjöblad, Managing Director BioGaia: 46 8 555 293 00

BioGaia is an innovative Swedish healthcare company that develops,
markets and sells probiotic products with documented health benefits.
The products are sold through local distribution partners in around
90 countries worldwide. The class B share of the Parent Company
BioGaia AB is quoted on the Mid Cap list of Nasdaq OMX Nordic
Exchange Stockholm.

BioGaia AB Box 3242. SE-103 64 STOCKHOLM Street address: Kungsbroplan
3, Stockholm Telephone: +46 8 555 293 00, Corp. identity no.
556380-8723. (


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.